Agios Gordios Beach Corfu Closures Hit Local Businesses

Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs. Our mature and unique understanding of the science is foundational to. At Agios, we are studying how PK activation could potentially benefit people with SCD. PK activation modulates 2,3-diphosphoglycerate (2,3-DPG) levels in RBCs which reduces hemoglobin S. Agios is committed to creating value for shareholders by creating value for patients and healthcare providers. Find out how in our latest press releases and SEC filings, upcoming events and other. “In 2025, Agios delivered another year of strong and consistent execution across our portfolio, marking meaningful progress toward our goal of becoming a sustainable and diversified rare disease. Agios was founded in 2008 to unlock a new field of discovery in cellular metabolism. This singular focus on metabolic disease has taken us from the development of precision therapies in oncology to.

Nov 3, 2025 · Agios is presenting new preclinical and clinical data on mitapivat, the company’s first-in-class pyruvate kinase (PK) activator, along with research from two Agios-supported advisory councils. Jan 13, 2025 · In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X. May 1, 2025 · Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a.